The alternative RelB NF-κB subunit is a novel critical player in diffuse large B-cell lymphoma.
2022 Jan 20
Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma.
2021 Jan 7
PD-1/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas.
2019 May 30
Homeobox NKX2-3 promotes marginal-zone lymphomagenesis by activating B-cell receptor signalling and shaping lymphocyte dynamics.
2016 Jun 14